Suppr超能文献

胶质母细胞瘤免疫治疗的转化图谱:用基础科学证据指导临床实践。

Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.

机构信息

Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, 460 W 12th Avenue, BRT 550, Columbus, OH, 43210, USA.

出版信息

J Hematol Oncol. 2022 Jun 11;15(1):80. doi: 10.1186/s13045-022-01298-0.

Abstract

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the most difficult cancers to treat in both the primary and recurrent settings. GBM presents a unique therapeutic challenge given the immune-privileged environment of the brain and the aggressive nature of the disease. Furthermore, it can change phenotypes throughout the course of disease-switching between mesenchymal, neural, and classic gene signatures, each with specific markers and mechanisms of resistance. Recent advancements in the field of immunotherapy-which utilizes strategies to reenergize or alter the immune system to target cancer-have shown striking results in patients with many types of malignancy. Immune checkpoint inhibitors, adoptive cellular therapy, cellular and peptide vaccines, and other technologies provide clinicians with a vast array of tools to design highly individualized treatment and potential for combination strategies. There are currently over 80 active clinical trials evaluating immunotherapies for GBM, often in combination with standard secondary treatment options including re-resection and anti-angiogenic agents, such as bevacizumab. This review will provide a clinically focused overview of the immune environment present in GBM, which is frequently immunosuppressive and characterized by M2 macrophages, T cell exhaustion, enhanced transforming growth factor-β signaling, and others. We will also outline existing immunotherapeutic strategies, with a special focus on immune checkpoint inhibitors, chimeric antigen receptor therapy, and dendritic cell vaccines. Finally, we will summarize key discoveries in the field and discuss currently active clinical trials, including combination strategies, burgeoning technology like nucleic acid and nanoparticle therapy, and novel anticancer vaccines. This review aims to provide the most updated summary of the field of immunotherapy for GBM and offer both historical perspective and future directions to help inform clinical practice.

摘要

尽管癌症治疗在最近取得了进展,但胶质母细胞瘤(GBM)仍然是原发性和复发性治疗中最难治疗的癌症之一。由于大脑的免疫特权环境和疾病的侵袭性,GBM 带来了独特的治疗挑战。此外,它可以在疾病过程中改变表型——在间充质、神经和经典基因特征之间切换,每种特征都具有特定的标志物和耐药机制。免疫疗法领域的最新进展——利用策略来重新激活或改变免疫系统以靶向癌症——在许多类型的恶性肿瘤患者中显示出了惊人的效果。免疫检查点抑制剂、过继细胞疗法、细胞和肽疫苗以及其他技术为临床医生提供了大量工具来设计高度个体化的治疗方案和潜在的联合策略。目前有超过 80 项针对 GBM 的免疫疗法的临床试验正在进行中,这些试验通常与标准的二线治疗方案结合使用,包括再次切除和抗血管生成药物,如贝伐单抗。这篇综述将提供一个针对 GBM 免疫环境的临床重点概述,该环境通常具有免疫抑制性,其特征是 M2 巨噬细胞、T 细胞耗竭、增强的转化生长因子-β信号等。我们还将概述现有的免疫治疗策略,特别关注免疫检查点抑制剂、嵌合抗原受体疗法和树突状细胞疫苗。最后,我们将总结该领域的关键发现,并讨论目前正在进行的临床试验,包括联合策略、崭露头角的技术,如核酸和纳米粒子治疗以及新型抗癌疫苗。本综述旨在提供 GBM 免疫治疗领域的最新总结,并提供历史视角和未来方向,以帮助指导临床实践。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00b8/9188714/d961496c7331/13045_2022_1298_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验